Document Detail


Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide.
MedLine Citation:
PMID:  7547508     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The retinoid N-(hydroxyphenyl) retinamide (4-HPR) appears to be a promising tool for chemoprevention of breast carcinoma, and clinical trials to evaluate its effect are in progress. However, its action on tumor cells has remained largely undefined. We report here that 4-HPR induced apoptosis and/or differentiation in breast cancer cell lines, independent of hormone receptor status and retinoic acid receptor expression, although it was slightly more efficient in inhibiting proliferation of estrogen receptor-positive cells. 4-HPR up-modulated expression of several differentiation markers (class 1 HLA, laminin, and beta 1 integrin chain) and down-regulated expression of molecules associated with tumor progression, including the p185/HER2 oncoprotein, the epidermal growth factor receptor, and the M(r) 67,000 laminin receptor. These data suggest that 4-HPR could exert a beneficial effect by inhibiting cell proliferation and modulating breast tumor aggressiveness.
Authors:
R Pellegrini; A Mariotti; E Tagliabue; R Bressan; G Bunone; D Coradini; G Della Valle; F Formelli; L Cleris; P Radice
Related Documents :
24338698 - Wiskott-aldrich syndrome protein deficiency in natural killer and dendritic cells affec...
23873478 - The role of p53 in combination radioimmunotherapy with 64cu-dota-cetuximab and cisplati...
23670728 - Effect of tumor microenvironment on tumor vegf during anti-vegf treatment: systems biol...
15858448 - A case of carcinosarcoma of the breast.
11810448 - Electron microscopic and immunohistochemical studies of gastrointestinal stromal tumors.
8281518 - A mesenchymal chondrosarcoma of a child with the reciprocal translocation (11;22)(q24;q...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research     Volume:  6     ISSN:  1044-9523     ISO Abbreviation:  Cell Growth Differ.     Publication Date:  1995 Jul 
Date Detail:
Created Date:  1995-11-09     Completed Date:  1995-11-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9100024     Medline TA:  Cell Growth Differ     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  863-9     Citation Subset:  IM    
Affiliation:
Dipartimento di Oncologia Sperimentale, Istituto Nazionale Tumori, Milano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticarcinogenic Agents / pharmacology*
Apoptosis / drug effects
Blotting, Northern
Breast Neoplasms / pathology*
Cell Differentiation / drug effects
Cell Division / drug effects
Fenretinide / pharmacology*
Gene Expression / physiology
Humans
Receptors, Estrogen / physiology
Receptors, Progesterone / physiology
Tumor Cells, Cultured / drug effects
Tumor Markers, Biological*
Chemical
Reg. No./Substance:
0/Anticarcinogenic Agents; 0/Receptors, Estrogen; 0/Receptors, Progesterone; 0/Tumor Markers, Biological; 65646-68-6/Fenretinide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Increased glycosylation of beta 1 integrins affects the interaction of transformed S115 mammary epit...
Next Document:  Regulation of cathepsin D gene expression in HL-60 cells by retinoic acid and calcitriol.